FMR LLC filed Amendment No. 3 to its Schedule 13G with the SEC on November 4, 2026, disclosing beneficial ownership of common stock in Charles River Laboratories International, Inc. as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: FMR LLC reported 5,922,755.21 shares of Charles River Laboratories common stock beneficially owned, representing 12.4% of the class.
  • Sole voting power: FMR LLC holds sole voting power over 5,850,399.37 shares, according to the filing.
  • Sole dispositive power: FMR LLC holds sole dispositive power over 5,922,755.21 shares, with no shared dispositive power reported.
  • Abigail P. Johnson co-reports: Abigail P. Johnson is listed as a separate reporting person with the same 5,922,755.21 shares and 12.4% of class, holding sole dispositive power but zero sole voting power.
  • Event date: The filing event date triggering this amendment is September 30, 2026.
  • Third-party interests: The filing states that one or more other persons have the right to receive dividends or sale proceeds from the common stock, but no single other person's interest exceeds 5% of total outstanding shares.

FMR LLC and Abigail P. Johnson Disclose Combined Position in Charles River Laboratories

FMR LLC, a Delaware-organized holding company located at 245 Summer Street, Boston, Massachusetts 02210, filed Amendment No. 3 to its Schedule 13G on November 4, 2026, covering its position in Charles River Laboratories International, Inc. (CUSIP 159864107), whose principal executive offices are at 251 Ballardvale St, Wilmington, MA 01887. The filing was triggered by an event dated September 30, 2026.

According to the filing, FMR LLC beneficially owns 5,922,755.21 shares of common stock, constituting 12.4% of the outstanding class. FMR LLC reports sole voting power over 5,850,399.37 shares and sole dispositive power over the full 5,922,755.21 shares. Shared voting and shared dispositive power are each reported as 0.00. Abigail P. Johnson is identified as a separate reporting person with beneficial ownership of the same 5,922,755.21 shares and the same 12.4% of class, with sole dispositive power over all such shares but zero sole voting power attributed directly to her.

The filing certifies, as required under Schedule 13G, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The statement was signed by Stephanie J. Brown, acting under separate powers of attorney on behalf of both FMR LLC and Abigail P. Johnson. The filing identifies FMR LLC as a parent holding company and directs readers to Exhibit 99 for the identification and classification of relevant subsidiaries.

What Was Disclosed

FMR LLC and Abigail P. Johnson jointly filed Amendment No. 3 to Schedule 13G, disclosing aggregate beneficial ownership of 5,922,755.21 shares, or 12.4%, of Charles River Laboratories International, Inc. common stock as of September 30, 2026, with no shared voting or dispositive power reported.